Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL over exp |
| Therapy | Mecbotamab Vedotin |
| Indication/Tumor Type | adenoid cystic carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL over exp | adenoid cystic carcinoma | predicted - sensitive | Mecbotamab Vedotin | Case Reports/Case Series | Actionable | In a Phase I trial, Mecbotamab Vedotin treatment resulted in stable disease with radiological and clinical improvement in a patient with adenoid cystic carcinoma with high AXL expression (PMID: 38579194; NCT03425279). | 38579194 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38579194) | First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. | Full reference... |